Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

CRISPR-engineered T cells in patients with refractory cancer.

Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH.

Science. 2020 Feb 6. pii: eaba7365. doi: 10.1126/science.aba7365. [Epub ahead of print]

PMID:
32029687
2.

Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant.

Aziz MD, Shah J, Kapoor U, Dimopoulos C, Anand S, Augustine A, Ayuk F, Chaudhry M, Chen YB, Choe HK, Etra A, Gergoudis S, Hartwell MJ, Hexner EO, Hogan WJ, Kitko CL, Kowalyk S, Kröger N, Merli P, Morales G, Nakamura R, Ordemann R, Pulsipher MA, Qayed M, Reshef R, Rösler W, Schechter T, Schreiner E, Srinagesh H, Wölfl M, Wudhikarn K, Yanik G, Young R, Özbek U, Ferrara JLM, Levine JE.

Leukemia. 2020 Feb 4. doi: 10.1038/s41375-020-0726-z. [Epub ahead of print]

PMID:
32020045
3.

The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease.

Srinagesh HK, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, Choe HK, DeFilipp Z, Etra A, Grupp SA, Hartwell MJ, Hexner EO, Hogan WJ, Karol AB, Kasikis S, Kitko CL, Kowalyk S, Lin JY, Major-Monfried H, Mielke S, Merli P, Morales G, Ordemann R, Pulsipher MA, Qayed M, Reddy P, Reshef R, Rösler W, Sandhu KS, Schechter T, Shah J, Sigel K, Weber D, Wölfl M, Wudhikarn K, Young R, Levine JE, Ferrara JLM.

Blood Adv. 2019 Dec 10;3(23):4034-4042. doi: 10.1182/bloodadvances.2019000791.

4.

Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia.

Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL.

J Clin Oncol. 2020 Feb 10;38(5):415-422. doi: 10.1200/JCO.19.01892. Epub 2019 Dec 9.

PMID:
31815579
5.

Persistent Mixed Donor Chimerism following Double Umbilical Cord Transplantation in a Patient with T-Cell Prolymphocytic Leukemia.

Mistry RH, Hexner EO, Mangan JK.

Case Rep Hematol. 2019 Sep 11;2019:8437805. doi: 10.1155/2019/8437805. eCollection 2019.

6.

Hodgkin lymphoma patients have an increased incidence of idiopathic acquired aplastic anemia.

Linaburg T, Davis AR, Frey NV, Khawaja MR, Landsburg DJ, Schuster SJ, Svoboda J, Li Y, Borovskiy Y, Olson TS, Bagg A, Hexner EO, Babushok DV.

PLoS One. 2019 Apr 5;14(4):e0215021. doi: 10.1371/journal.pone.0215021. eCollection 2019.

7.

Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.

Reshef R, Ganetsky A, Acosta EP, Blauser R, Crisalli L, McGraw J, Frey NV, Hexner EO, Hoxie JA, Loren AW, Luger SM, Mangan J, Stadtmauer EA, Mick R, Vonderheide RH, Porter DL.

Biol Blood Marrow Transplant. 2019 Mar;25(3):515-521. doi: 10.1016/j.bbmt.2018.09.034. Epub 2018 Oct 10.

PMID:
30315941
8.

Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.

Ganetsky A, Han JH, Hughes ME, Babushok DV, Frey NV, Gill SI, Hexner EO, Loren AW, Luger SM, Mangan JK, Martin ME, Smith J, Freyer CW, Gilmar C, Schuster M, Stadtmauer EA, Porter DL.

Clin Infect Dis. 2019 May 30;68(12):2003-2009. doi: 10.1093/cid/ciy822.

9.

Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response.

Babushok DV, Nelson EJ, Morrissette JJD, Joshi S, Palmer MB, Frank D, Cambor CL, Hexner EO.

Leuk Lymphoma. 2019 Mar;60(3):852-855. doi: 10.1080/10428194.2018.1509319. Epub 2018 Sep 19. No abstract available.

PMID:
30227762
10.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL.

JCI Insight. 2018 Aug 23;3(16). pii: 124015. doi: 10.1172/jci.insight.124015. eCollection 2018 Aug 23. No abstract available.

11.

Germline duplication of ATG2B and GSKIP genes is not required for the familial myeloid malignancy syndrome associated with the duplication of chromosome 14q32.

Babushok DV, Stanley NL, Morrissette JJD, Lieberman DB, Olson TS, Chou ST, Hexner EO.

Leukemia. 2018 Dec;32(12):2720-2723. doi: 10.1038/s41375-018-0231-9. Epub 2018 Aug 7. No abstract available.

12.

Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract.

Ganetsky A, Frey NV, Hexner EO, Loren AW, Gill SI, Luger SM, Mangan JK, Martin ME, Babushok DV, Drobyski WR, Smith J, Timlin C, Freyer CW, Stadtmauer EA, Porter DL.

Bone Marrow Transplant. 2019 Feb;54(2):212-217. doi: 10.1038/s41409-018-0236-z. Epub 2018 May 24.

PMID:
29795429
13.

Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.

Kasner MT, Mick R, Jeschke GR, Carabasi M, Filicko-O'Hara J, Flomenberg N, Frey NV, Hexner EO, Luger SM, Loren AW, Mangan JK, Wagner JL, Weiss M, Carroll M, Perl AE.

Invest New Drugs. 2018 Aug;36(4):657-666. doi: 10.1007/s10637-018-0585-x. Epub 2018 Apr 2.

14.

MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.

Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera YA, Hogan WJ, Wölfl M, Qayed M, Hexner EO, Wudhikarn K, Ordemann R, Young R, Shah J, Hartwell MJ, Chaudhry MS, Aziz M, Etra A, Yanik GA, Kröger N, Weber D, Chen YB, Nakamura R, Rösler W, Kitko CL, Harris AC, Pulsipher M, Reshef R, Kowalyk S, Morales G, Torres I, Özbek U, Ferrara JLM, Levine JE.

Blood. 2018 Jun 21;131(25):2846-2855. doi: 10.1182/blood-2018-01-822957. Epub 2018 Mar 15.

15.

Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors.

Crisalli LM, Hinkle JT, Walling CC, Sell M, Frey NV, Hexner EO, Loren AW, Luger SM, Stadtmauer EA, Porter DL, Reshef R.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1203-1208. doi: 10.1016/j.bbmt.2018.01.037. Epub 2018 Feb 2.

16.

Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Soderquist CR, Ewalt MD, Czuchlewski DR, Geyer JT, Rogers HJ, Hsi ED, Wang SA, Bueso-Ramos CE, Orazi A, Arber DA, Hexner EO, Babushok DV, Bagg A.

Mod Pathol. 2018 May;31(5):690-704. doi: 10.1038/modpathol.2017.182. Epub 2018 Jan 12.

17.

CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.

Lv K, Jiang J, Donaghy R, Riling CR, Cheng Y, Chandra V, Rozenova K, An W, Mohapatra BC, Goetz BT, Pillai V, Han X, Todd EA, Jeschke GR, Langdon WY, Kumar S, Hexner EO, Band H, Tong W.

Genes Dev. 2017 May 15;31(10):1007-1023. doi: 10.1101/gad.297135.117. Epub 2017 Jun 13.

18.

Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension.

Reilly CR, Babushok DV, Martin K, Spivak JL, Streiff M, Bahirwani R, Mondschein J, Stein B, Moliterno A, Hexner EO.

Am J Hematol. 2017 Sep;92(9):909-914. doi: 10.1002/ajh.24798. Epub 2017 Jul 26.

19.

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.

Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H; COMFORT-I investigators.

J Hematol Oncol. 2017 Feb 22;10(1):55. doi: 10.1186/s13045-017-0417-z.

20.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL.

JCI Insight. 2017 Feb 9;2(3):e89798. doi: 10.1172/jci.insight.89798. Erratum in: JCI Insight. 2018 Aug 23;3(16):.

21.

The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.

Gupta V, Harrison C, Hexner EO, Al-Ali HK, Foltz L, Montgomery M, Sun W, Gopalakrishna P, Kantarjian H, Verstovsek S.

Haematologica. 2016 Dec;101(12):e482-e484. Epub 2016 Sep 1. No abstract available.

22.

Bilateral facial paralysis in a non-Hodgkin lymphoma during remission period: a rare but an important condition to be investigated.

Bugueno JM, Jacobs BE, Hexner EO, Greenberg MS.

Am J Emerg Med. 2016 Dec;34(12):2463.e5-2463.e7. doi: 10.1016/j.ajem.2016.06.020. Epub 2016 Jun 7. No abstract available.

PMID:
27321933
23.

Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation.

Yam C, Crisalli L, Luger SM, Loren AW, Hexner EO, Frey NV, Mangan JK, Gao A, Stadtmauer EA, Porter DL, Reshef R.

Am J Hematol. 2016 Sep;91(9):883-7. doi: 10.1002/ajh.24424. Epub 2016 Jul 12.

24.

Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment.

Hexner EO, Luger SM, Reshef R, Jeschke GR, Mangan JK, Frey NV, Frank DM, Richman LP, Vonderheide RH, Aqui NA, Rosenbach M, Zhang Y, Chew A, Loren AW, Stadtmauer EA, Levine BL, June CH, Emerson SG, Porter DL.

Am J Hematol. 2016 May;91(5):453-60. doi: 10.1002/ajh.24303. Epub 2016 Apr 4.

25.

The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation.

Meng L, Bai Z, He S, Mochizuki K, Liu Y, Purushe J, Sun H, Wang J, Yagita H, Mineishi S, Fung H, Yanik GA, Caricchio R, Fan X, Crisalli LM, Hexner EO, Reshef R, Zhang Y, Zhang Y.

J Immunol. 2016 Feb 1;196(3):1070-80. doi: 10.4049/jimmunol.1501310. Epub 2015 Dec 28.

26.

Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation.

Ganetsky A, Shah A, Miano TA, Hwang WT, He J, Loren AW, Hexner EO, Frey NV, Porter DL, Reshef R.

Bone Marrow Transplant. 2016 Apr;51(4):568-72. doi: 10.1038/bmt.2015.323. Epub 2015 Dec 21.

27.

High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.

Reshef R, Huffman AP, Gao A, Luskin MR, Frey NV, Gill SI, Hexner EO, Kambayashi T, Loren AW, Luger SM, Mangan JK, Nasta SD, Richman LP, Sell M, Stadtmauer EA, Vonderheide RH, Mick R, Porter DL.

J Clin Oncol. 2015 Jul 20;33(21):2392-8. doi: 10.1200/JCO.2014.60.1203. Epub 2015 Jun 8.

28.

AUF-1 and YB-1 independently regulate β-globin mRNA in developing erythroid cells through interactions with poly(A)-binding protein.

van Zalen S, Lombardi AA, Jeschke GR, Hexner EO, Russell JE.

Mech Dev. 2015 May;136:40-52. doi: 10.1016/j.mod.2015.02.003. Epub 2015 Feb 23.

29.

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H; COMFORT-I investigators.

Haematologica. 2015 Apr;100(4):479-88. doi: 10.3324/haematol.2014.115840. Epub 2015 Jan 23.

30.

Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.

Hexner EO, Mascarenhas J, Prchal J, Roboz GJ, Baer MR, Ritchie EK, Leibowitz D, Demakos EP, Miller C, Siuty J, Kleczko J, Price L, Jeschke G, Weinberg R, Basu T, Pahl HL, Orazi A, Najfeld V, Marchioli R, Goldberg JD, Silverman LR, Hoffman R.

Leuk Lymphoma. 2015;56(9):2543-51. doi: 10.3109/10428194.2014.1001986. Epub 2015 Feb 20.

31.

Acute cholecystitis is a common complication after allogeneic stem cell transplantation and is associated with the use of total parenteral nutrition.

Bagley SJ, Sehgal AR, Gill S, Frey NV, Hexner EO, Loren AW, Mangan JK, Porter DL, Stadtmauer EA, Reshef R, Luger SM.

Biol Blood Marrow Transplant. 2015 Apr;21(4):768-71. doi: 10.1016/j.bbmt.2014.12.005. Epub 2014 Dec 24.

32.

Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.

Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, Horowitz MM, Lee SJ, Levine JE, MacMillan ML, Martin PJ, Mendizabal AM, Nakamura R, Pasquini MC, Weisdorf DJ, Westervelt P, Ho VT.

Blood. 2014 Nov 20;124(22):3221-7; quiz 3335. doi: 10.1182/blood-2014-06-577023. Epub 2014 Aug 28.

33.

A common, under-recognized cause of elevated serum erythropoietin.

Babushok DV, Cardamone D, Rulander N, Master SR, Hexner EO.

Am J Med. 2014 Dec;127(12):e7-8. doi: 10.1016/j.amjmed.2014.08.006. Epub 2014 Aug 19. No abstract available.

34.

Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.

Reshef R, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Gill SI, Vassilev P, Lafferty KA, Smith J, Van Deerlin VM, Mick R, Porter DL.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1758-66. doi: 10.1016/j.bbmt.2014.07.003. Epub 2014 Jul 10.

35.

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM.

Haematologica. 2013 Dec;98(12):1865-71. doi: 10.3324/haematol.2013.092155. Epub 2013 Sep 13.

36.

Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens.

Landsburg DJ, Stadtmauer E, Loren A, Goldstein S, Frey N, Nasta SD, Porter DL, Tsai DE, Perl AE, Hexner EO, Luger S.

Am J Hematol. 2013 Aug;88(8):657-60. doi: 10.1002/ajh.23468. Epub 2013 Jun 5.

37.

Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.

Kumar AJ, Hexner EO, Frey NV, Luger SM, Loren AW, Reshef R, Boyer J, Smith J, Stadtmauer EA, Levine BL, June CH, Porter DL, Goldstein SC.

Biol Blood Marrow Transplant. 2013 Jul;19(7):1094-101. doi: 10.1016/j.bbmt.2013.04.021. Epub 2013 Apr 28.

38.

Myelofibrosis 2012: it's complicated.

Hubbeling HG, Frank DM, Hexner EO.

Ther Adv Hematol. 2012 Jun;3(3):131-46. doi: 10.1177/2040620712437754.

39.

Intrinsic resistance to JAK2 inhibition in myelofibrosis.

Kalota A, Jeschke GR, Carroll M, Hexner EO.

Clin Cancer Res. 2013 Apr 1;19(7):1729-39. doi: 10.1158/1078-0432.CCR-12-1907. Epub 2013 Feb 5.

40.

Characteristics and outcome of acute myeloid leukemia in patients with a prior history of autoimmune disease.

DiNardo CD, Ogdie A, Hexner EO, Frey NV, Loren AW, Luger SM.

Leuk Lymphoma. 2013 Jun;54(6):1235-41. doi: 10.3109/10428194.2012.736982. Epub 2013 Feb 19.

PMID:
23216270
41.

Maintenance of hematopoietic stem cells through regulation of Wnt and mTOR pathways.

Huang J, Nguyen-McCarty M, Hexner EO, Danet-Desnoyers G, Klein PS.

Nat Med. 2012 Dec;18(12):1778-85. doi: 10.1038/nm.2984. Epub 2012 Nov 11.

42.

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie JA, Vonderheide RH, Porter DL.

N Engl J Med. 2012 Jul 12;367(2):135-45. doi: 10.1056/NEJMoa1201248.

43.

Umbilical cord blood transplantation in cancer therapy.

Hexner EO.

Clin Adv Hematol Oncol. 2012 May;10(5):319-20. No abstract available.

PMID:
22706541
44.

High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT.

Tizon R, Frey N, Heitjan DF, Tan KS, Goldstein SC, Hexner EO, Loren A, Luger SM, Reshef R, Tsai D, Vogl D, Davis J, Vozniak M, Fuchs B, Stadtmauer EA, Porter DL.

Bone Marrow Transplant. 2012 Oct;47(10):1332-7. doi: 10.1038/bmt.2011.260. Epub 2012 Feb 6.

PMID:
22307018
45.

AUF-1 and YB-1 are critical determinants of β-globin mRNA expression in erythroid cells.

van Zalen S, Jeschke GR, Hexner EO, Russell JE.

Blood. 2012 Jan 26;119(4):1045-53. doi: 10.1182/blood-2011-10-387316. Epub 2011 Dec 1.

46.

Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD.

Rager A, Frey N, Goldstein SC, Reshef R, Hexner EO, Loren A, Luger SM, Perl A, Tsai D, Davis J, Vozniak M, Smith J, Stadtmauer EA, Porter DL.

Bone Marrow Transplant. 2011 Mar;46(3):430-5. doi: 10.1038/bmt.2010.117. Epub 2010 May 24.

47.

AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2.

Wang W, Schwemmers S, Hexner EO, Pahl HL.

Blood. 2010 Jul 15;116(2):254-66. doi: 10.1182/blood-2009-11-254664. Epub 2010 Mar 25.

48.

A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.

Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM.

Clin Cancer Res. 2009 Nov 1;15(21):6732-9. doi: 10.1158/1078-0432.CCR-09-0842. Epub 2009 Oct 20.

49.

Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantation.

Porter DL, Hexner EO, Cooley S, Miller JS.

Cancer Treat Res. 2009;144:497-537. doi: 10.1007/978-0-387-78580-6_20. Review. No abstract available.

PMID:
19779876
50.

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.

Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, Yang S, Angeles T, Emerson SG, Carroll M, Ruggeri B, Dobrzanski P.

Blood. 2008 Jun 15;111(12):5663-71. Epub 2007 Nov 5.

Supplemental Content

Loading ...
Support Center